Hetero, a global leader in pharmaceutical innovation,successfully hosted its highly anticipated scientific symposium, Reset Diabesity,
bringing together more than 300 physicians from across Kenya to address the
growing burden of diabetes, obesity, and related metabolic disorders. The event
marked a significant milestone in the country’s evolving approach to managing these
interconnected conditions and featured the official Kenyan launch of Truglyx
(semaglutide injection), Hetero’s once-weekly GLP-1 receptor agonist.
Designed to foster multidisciplinary dialogue and clinical excellence, the symposium
focused on the emerging concept of Diabesity the close and complex relationship
between obesity, type 2 diabetes, and associated cardio-renal-metabolic
complications. Truglyx was introduced as an important therapeutic option aimed at
addressing both glycaemic control and weight management while supporting broader
metabolic health outcomes.
The symposium was moderated by Dr. Paul Ngugi, Consultant Physician and
Endocrinologist at The Nairobi Hospital, and featured a distinguished faculty of
leading specialists. Dr. Swaleh Breik Misfar, Consultant Interventional Cardiologist
affiliated with Aga Khan Hospital Mombasa, shared insights into the cardiovascular
implications of Cardio-Renal-Metabolic (CKM) syndrome, while Dr. Kirtida Acharya,
Consultant Endocrinologist from National Women’s Hospital and MP Shah Hospital,
explored the metabolic drivers underlying the disease continuum.
An engaging multidisciplinary panel discussion followed, featuring Dr. Miriam Murithi,
Consultant Gastroenterologist, and Dr. Sood Mahamed (H.S.C.), Consultant
Nephrologist, who highlighted the multisystem impact of CKM syndrome and the
importance of integrated patient management.
Dr. Acharya emphasized that diabetes and obesity should not be viewed as isolated
conditions but rather as manifestations of a broader metabolic dysfunction. She
noted that these diseases are closely linked to several serious chronic conditions,
including cardiovascular disease, chronic kidney disease, certain cancers, and
mental health disorders, many of which are influenced by lifestyle and environmental factors
A central focus of the symposium was the introduction of Truglyx (semaglutide),
